|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
To evaluate the safety and tolerability of CD19-CAR-DNT cells infusion in subjects with relapsed/refractory B-cell non-Hodgkin's Lymphoma
100 Clinical Results associated with Zhejiang Ruijiamei Biotechnologies, Co., Ltd.
0 Patents (Medical) associated with Zhejiang Ruijiamei Biotechnologies, Co., Ltd.
100 Deals associated with Zhejiang Ruijiamei Biotechnologies, Co., Ltd.
100 Translational Medicine associated with Zhejiang Ruijiamei Biotechnologies, Co., Ltd.